Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 269

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 269
---
, respectively. Stock-based compensation expense has been reported in the Company's condensed consolidated statements of operations and comprehensive loss within general and administrative expenses.

7.Net loss per share

Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows:

|                                                                      |   | Three months ended June 30, 
                        2025 |   |     |   |       2024 |   |     |   | Six months ended June 30, 
                      2025 |   |     |   |       2024 |   |
|:---------------------------------------------------------------------|:--|----------------------------:|:--|:----|:--|-----------:|:--|:----|:--|--------------------------:|:--|:----|:--|-----------:|:--|
| Net loss attributable to shareholders                                | $ |                  (6,176,084 | ) |     | $ | (3,632,859 | ) |     | $ |               (11,278,492 | ) |     | $ | (5,340,217 | ) |
| Weighted average number of common shares outstanding during the year |   |                  14,284,261 |   |     |   |  8,167,993 |   |     |   |                13,853,305 |   |     |   |  8,122,333 |   |
| Basic and diluted net loss per share attributable to shareholders    | $ |                       (0.43 | ) |     | $ |      (0.44 | ) |     | $ |                     (0.81 | ) |     | $ |      (0.66 | ) |

The Company's potentially dilutive securities for the three and six months ended June 30, 2025 and 2024, include stock options, warrants, and notes payable. The Company excluded the potential ordinary shares outstanding at each period end from the computation of diluted net loss per share attributable to ordinary shareholders for the three and six months ended June 30, 2025 and 2024 because including them would have had an anti-dilutive effect.

<div align='center'>F-38

CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD.PURSUANT TO 17 C.F.R. SECTION 200.83</div>

8.Related party transactions

On October 18, 2023, the Company signed an agreement with RBx Capital, LP ("RB